Evidence map›Paper›PMID 32887587›Full record

ArticleMicrobial cell factories2020

Exploring the use of leucine zippers for the generation of a new class of inclusion bodies for pharma and biotechnological applications.

Ramon Roca-Pinilla, Sara Fortuna, Antonino Natalello, Alejandro Sánchez-Chardi, Diletta Ami, Anna Arís, Elena Garcia-Fruitós

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Coiled-Coil Based Inclusion Bodies and Their Potential Applications.Frontiers in bioengineering and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ramon Roca-PinillaDepartment of Ruminant Production, Institute of Agriculture and Food Research and Technology (IRTA), 08140, Caldes de Montbui, Spain.
Sara FortunaDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127, Trieste, Italy.
Antonino NatalelloDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126, Milan, Italy.
Alejandro Sánchez-ChardiDepartment of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona (UB), 08028, Barcelona, Spain.
Diletta AmiDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126, Milan, Italy.
Anna ArísDepartment of Ruminant Production, Institute of Agriculture and Food Research and Technology (IRTA), 08140, Caldes de Montbui, Spain. anna.aris@irta.cat.
Elena Garcia-FruitósDepartment of Ruminant Production, Institute of Agriculture and Food Research and Technology (IRTA), 08140, Caldes de Montbui, Spain. elena.garcia@irta.cat.ORCID http://orcid.org/0000-0001-7498-4864
Institute of Agrifood Research and Technology · ESUniversity of Milano-Bicocca · ITUniversitat Autònoma de Barcelona · ESUniversity of Trieste · IT

Funding

AGAUR PhD FellowshipCINECA 2017CINECA N. HP10BTJPERInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria post-doctoral fellowshipIRTA IRTA Cutting Edge ResearchUniversità degli Studi di Milano-Bicocca post-doctoral fellowship (Assegno di Ricerca)
6 · The paper itself

Abstract

backgroundInclusion bodies (IBs) are biologically active protein aggregates forming natural nanoparticles with a high stability and a slow-release behavior. Because of their nature, IBs have been explored to be used as biocatalysts, in tissue engineering, and also for human and animal therapies. To improve the production and biological efficiency of this nanomaterial, a wide range of aggregation tags have been evaluated. However, so far, the presence in the IBs of bacterial impurities such as lipids and other proteins coexisting with the recombinant product has been poorly studied. These impurities could strongly limit the potential of IB applications, being necessary to control the composition of these bacterial nanoparticles. Thus, we have explored the use of leucine zippers as alternative tags to promote not only aggregation but also the generation of a new type of IB-like protein nanoparticles with improved physicochemical properties.

resultsThree different protein constructs, named GFP, J-GFP-F and J/F-GFP were engineered. J-GFP-F corresponded to a GFP flanked by two leucine zippers (Jun and Fos); J/F-GFP was formed coexpressing a GFP fused to Jun leucine zipper (J-GFP) and a GFP fused to a Fos leucine zipper (F-GFP); and, finally, GFP was used as a control without any tag. All of them were expressed in Escherichia coli and formed IBs, where the aggregation tendency was especially high for J/F-GFP. Moreover, those IBs formed by J-GFP-F and J/F-GFP constructs were smaller, rougher, and more amorphous than GFP ones, increasing surface/mass ratio and, therefore, surface for protein release. Although the lipid and carbohydrate content were not reduced with the addition of leucine zippers, interesting differences were observed in the protein specific activity and conformation with the addition of Jun and Fos. Moreover, J-GFP-F and J/F-GFP nanoparticles were purer than GFP IBs in terms of protein content.

conclusionsThis study proved that the use of leucine zippers strategy allows the formation of IBs with an increased aggregation ratio and protein purity, as we observed with the J/F-GFP approach, and the formation of IBs with a higher specific activity, in the case of J-GFP-F IBs. Thus, overall, the use of leucine zippers seems to be a good system for the production of IBs with more promising characteristics useful for pharma or biotech applications.

Indexed as

Leucine ZippersBiotechnologyCell SurvivalEscherichia coliGenes, fosGenes, junGreen Fluorescent ProteinsInclusion BodiesNanoparticlesProtein ConformationProtein Interaction Domains and MotifsRecombinant Fusion ProteinsGreen Fluorescent ProteinsRecombinant Fusion ProteinsAggregationFosInclusion bodiesJunLeucine zippersPurityRecombinant protein

Identifiers

PMID32887587
PMCPMC7650227
OpenAlexW3083589904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.